Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CuttingEdge Bio who wrote (3192)	12/21/2020 7:24:11 PM
From: Felix B	of 3557

One does one determine when to does on PRN? I assume some it's some visual acuity rather than some biomarker? The reason I ask is REGN stance (I am paraphrasing) on bispecifics if its not bringing two targets together its better just do go with a mAb combo and tailor your formulation on some biomarker, PK, half life something) that you could take advantage of of using a cocktail which REGN is obviously capabable of however another company might favor a bispecific. I don't know enough of the eye biology if that makes sense but on a high level it does to me. If it simply was midosing on REGN party they should be able to coformulate their Ang ab with the right dose. If there is some MOA advantage of using a bispecific due to biology or something I am not appreciating, then please explain.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next